Join the 'Taxotere' group to help and get support from people like you. How it works
Taxotere Blog
| Tweet |
Drug Combo Might Fight Aggressive Breast Cancer More Safely
Posted 5 Oct 2011 by Drugs.com
WEDNESDAY, Oct. 5 – Treating women with an aggressive form of early stage breast cancer using Herceptin and chemotherapy, while not turning to a third type of drug known as an anthracycline, improves survival while posing less danger to the heart, researchers report. They tested three different regimens, one of which did not include any anthracyclines. When Herceptin is given with doxorubicin (Adriamycin), an anthracycline, toxic cardiac effects have been seen. "What the study shows is you have comparable effectiveness in a Herceptin-based regimen when you don't use the anthracyclines," said Dr. Dennis Slamon, director of clinical and translational research at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles. Earlier research of his led to the development of Herceptin (trastuzumab). He contends that the new regimen should be the new standard of care, ... Read more
Related support groups: Breast Cancer, Herceptin, Carboplatin, Adriamycin, Taxotere, Doxorubicin, Docetaxel, Adriamycin RDF, Docefrez, Adriamycin PFS, Carboplatin Novaplus, Paraplatin
Cancer Patients Should Ask Doctors to Use Simple Terms
Posted 28 Sep 2011 by Drugs.com
WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more
Related support groups: Cancer, Methotrexate, Provera, Breast Cancer, Lupron, Accutane, Depo-Provera, Prostate Cancer, Tamoxifen, Femara, Arimidex, Lupron Depot, Medroxyprogesterone, Claravis, Gleevec
Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph
Posted 4 Dec 2010 by Drugs.com
WEDNESDAY, Dec. 1 – A chemotherapy regimen already proven superior to other regimens for breast cancer that has spread to the lymph nodes may also work better for some women whose cancers haven't spread, a new study has found. When it came to these "node-negative" cancers, the drug combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said. The TAC regimen was better at keeping women alive and disease-free after a median follow up of almost six and a half years, the study found. ''For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said study co-author Dr. Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid. ... Read more
Related support groups: Breast Cancer, Taxotere, Docetaxel
FDA Approves New Taxotere (docetaxel) Injection Concentrate Formulation
Posted 11 Aug 2010 by Drugs.com
BRIDGEWATER, N.J., Aug. 5 /PRNewswire/ – Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages. Introduced more than 14 years ago, Taxotere is approved by the FDA for use in treating patients at specific stages of 5 types of cancer: metastatic and adjuvant breast cancer, metastatic androgen independent prostate cancer, advanced non-small cell lung cancer, advanced gastric adenocarcinoma and locally advanced squamous cell carcinoma of the head and neck. "This new formulation underscores the commitment sanofi-aventis has made to Taxotere and to healthcare professionals. We look forward to adding ... Read more
Ask a Question
Further Information
Related Condition Support Groups
Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Breast Cancer, Metastatic, Gastric Cancer, Head and Neck Cancer, Solid Tumors